State Key Laboratory of Medical Molecular Biology, Department of Physiology, Collaborative Innovation Center for Cancer Medicine, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Gastroenterology. 2015 Sep;149(3):741-52.e14. doi: 10.1053/j.gastro.2015.05.005. Epub 2015 May 14.
BACKGROUND & AIMS: Levels of the Golgi protein 73 (GP73) increase during development of hepatocellular carcinoma (HCC); GP73 is a serum marker for HCC. However, little is known about the mechanisms or effects of GP73 during hepatic carcinogenesis.
GP73 was overexpressed from a retroviral vector in HepG2 cells, which were analyzed in proliferation and migration assays. Xenograft tumors were grown from these cells in nude mice. The effects of monoclonal antibodies against GP73 were studied in mice and cell lines. GP73(-/-), GP73(+/-), and GP73(+/+) mice were given injections of diethylnitrosamine to induce liver injury. Levels of GP73 were reduced in MHCC97H, HCCLM3, and HepG2.215 cell lines using small hairpin RNAs; xenograft tumors were grown in mice from MHCC97H-small hairpin GP73 or MHCC97H-vector cells. We used microarray analysis to compare expression patterns between GP73-knockdown and control MHCC97H cells. We studied the effects of the mechanistic target of rapamycin (mTOR) inhibitor rapamycin on GP73 expression in different cancer cell lines and on growth of tumors in mice. Levels of GP73 and activated mTOR were quantified in human HCC tissues.
Xenograft tumors grown from HepG2 cells that expressed GP73 formed more rapidly and more metastases than control HepG2 cells in mice. A monoclonal antibody against GP73 reduced proliferation of HepG2 cells and growth of xenograft tumors in mice. GP73(-/-) mice had less liver damage after administration of diethylnitrosamine than GP73(+/-) or GP73(+/+) mice. In phosphatase and tensin homolog-null mouse embryonic fibroblasts with constitutively activated mTOR, GP73 was up-regulated compared with control mouse embryonic fibroblasts; this increase was reversed after incubation with rapamycin. Expression of GP73 also was reduced in HCC and other cancer cell lines incubated with rapamycin. mTORC1 appeared to regulate expression of GP73 in cell lines. Activated mTOR correlated with the level of GP73 in human HCC tissues. Injection of rapamycin slowed the growth of xenograft tumors from MHCC97H-vector cells, compared with MHCC97H-short hairpin GP73 cells.
Increased expression of GP73 promotes proliferation and migration of HCC cell lines and growth of xenograft tumors in mice. mTORC1 regulates the expression of GP73, so GP73 up-regulation can be blocked with rapamycin. mTOR inhibitors or other reagents that reduce the level or activity of GP73 might be developed for the treatment of HCC.
高尔基蛋白 73(GP73)在肝细胞癌(HCC)的发展过程中水平升高;GP73 是 HCC 的血清标志物。然而,GP73 在肝发生癌变过程中的机制或作用知之甚少。
通过逆转录病毒载体在 HepG2 细胞中转录表达 GP73,分析增殖和迁移试验中的 GP73。从小鼠体内异种移植这些细胞生长肿瘤。在小鼠和细胞系中研究针对 GP73 的单克隆抗体的作用。用二乙基亚硝胺给 GP73(-/-)、GP73(+/-)和 GP73(+/+)小鼠注射,诱导肝损伤。用短发夹 RNA 降低 MHCC97H、HCCLM3 和 HepG2.215 细胞系中的 GP73 水平;从小鼠 MHCC97H-短发夹 GP73 或 MHCC97H-载体细胞中生长异种移植肿瘤。我们使用微阵列分析比较 GP73 敲低和对照 MHCC97H 细胞之间的表达模式。我们研究了雷帕霉素(mTOR)抑制剂雷帕霉素对不同癌细胞系中 GP73 表达和肿瘤在小鼠中生长的影响。在人 HCC 组织中定量检测 GP73 和激活的 mTOR 水平。
在小鼠中,表达 GP73 的 HepG2 细胞异种移植肿瘤比对照 HepG2 细胞形成更快,转移更多。针对 GP73 的单克隆抗体减少了 HepG2 细胞的增殖和异种移植肿瘤在小鼠中的生长。与 GP73(+/-)或 GP73(+/+)小鼠相比,二乙基亚硝胺处理后的 GP73(-/-)小鼠肝损伤较少。在磷酸酶和张力蛋白同系物(PTEN)缺失的具有组成性激活 mTOR 的小鼠胚胎成纤维细胞中,与对照小鼠胚胎成纤维细胞相比,GP73 上调;用雷帕霉素孵育后,这种增加被逆转。雷帕霉素孵育还降低了 HCC 和其他癌细胞系中 GP73 的表达。mTORC1 似乎在细胞系中调节 GP73 的表达。在人 HCC 组织中,激活的 mTOR 与 GP73 水平相关。与 MHCC97H-short hairpin GP73 细胞相比,雷帕霉素注射减缓了 MHCC97H-vector 细胞异种移植肿瘤的生长。
GP73 的表达增加促进 HCC 细胞系的增殖和迁移以及异种移植肿瘤在小鼠中的生长。mTORC1 调节 GP73 的表达,因此可以用雷帕霉素阻断 GP73 的上调。降低 GP73 水平或活性的 mTOR 抑制剂或其他试剂可能会被开发用于治疗 HCC。